Mounjaro vs Zepbound: Same Molecule, Two Brands

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Published in the PlexusDx Education Hub, this comparison tackles a question that trips up many searchers: two brand names built on one molecule. Browse the Peptides & GLP-1 Education Hub

This is an independent editorial comparison; PlexusDx has no commercial relationship with Eli Lilly.

Mounjaro and Zepbound look like rivals, but they share the same active ingredient. As of April 2026, this comparison explains why one molecule wears two labels, how their indications diverge, what the trials showed, and why the genetics underneath are indifferent to the brand on the pen.

When two brands share one active ingredient

Both Mounjaro and Zepbound are GIP and GLP-1 dual receptor agonists marketed by Eli Lilly — the same tirzepatide molecule in each. Both act on the GLP-1 receptor across the pancreas, hypothalamus, and gut, slowing gastric emptying, blunting post-meal glucose, and increasing satiety, while adding agonism at the GIP receptor. The pharmacology is identical; what differs is how each is labeled and sold.

Why Eli Lilly sells tirzepatide under two names

Separate brand names let one active ingredient carry distinct FDA indications and distinct prescribing contexts. Mounjaro is the diabetes-labeled presentation; Zepbound is the weight-management-labeled presentation. That structure is common in this category and drives how each is prescribed, marketed, and — critically — covered by insurance, since payers key on the indication attached to the label.

Indication scope and what it changes

Mounjaro holds an FDA approval for type 2 diabetes granted in 2022. Zepbound was approved for chronic weight management in 2023 in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and in 2024 the FDA expanded its indication to include moderate-to-severe obstructive sleep apnea in adults with obesity. Those scopes govern on-label use and coverage.

Evidence split across SURPASS and SURMOUNT

Mounjaro was evaluated in the SURPASS program for glycemic and weight outcomes in type 2 diabetes, while Zepbound was evaluated in the SURMOUNT program for chronic weight management, with SURMOUNT-OSA covering obstructive sleep apnea. SURPASS also tested tirzepatide head-to-head against semaglutide 1 mg in type 2 diabetes. Because the trials targeted different populations and endpoints, each is read on its own terms.

Pricing when the molecule is identical

Even with a shared active ingredient, the two labels are priced separately: Mounjaro's U.S. list price is approximately $1,069 per month as of April 2026, and Zepbound's is approximately $1,059 per month over the same window (both Eli Lilly published pricing). Out-of-pocket cost still hinges on coverage, savings cards, the indication on the prescription, and compounded-alternative availability through a licensed pathway.

Genetics don't care which label is on the pen

Since the molecule is the same, the genetic terrain is identical too. Variants in GIPR, GLP1R, FTO, and MC4R influence baseline appetite regulation, satiety, and energy expenditure regardless of whether the label reads Mounjaro or Zepbound. These pathway-level markers do not predict response, but they map the biology tirzepatide acts on. PlexusDx offers tirzepatide through its Weight Management Protocols, including the Tirzepatide Injection protocol, and the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — GIPR, GLP1R, FTO, and MC4R included — so you start from your own baseline.

More from the Hub: Mounjaro cost comparison, Mounjaro savings options, how to obtain Mounjaro, and the Mounjaro injection format.

Editorial note: this article is educational. PlexusDx offers tirzepatide through its Weight Management Protocols and covers here the mechanism, evidence, and genetic context behind any decision to use it. The Precision Peptide Genetic Test shows how your genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

See the formats in the Weight Management Protocols, or begin with the Precision Peptide Genetic Test. Browse the Peptides & GLP-1 Education Hub

Frequently Asked Questions

If they're the same drug, why compare them at all?

Mounjaro and Zepbound share the tirzepatide molecule, so the comparison is really about labeling: different FDA indications, prescribing contexts, and coverage rules attach to each name. Understanding which label fits an intended use matters for on-label prescribing and for how insurers evaluate a claim, even though the pharmacology is identical.

Does one work better than the other?

Because both deliver the same active ingredient, differences in outcome trace to indication, dosing, and individual biology rather than the molecule itself. Trials targeted different populations and endpoints, so results are read per-trial. Individual response varies, and any comparison of results should be discussed with a provider.

Can the Precision Peptide Genetic Test distinguish between them?

No. Since Mounjaro and Zepbound are the same molecule, no test could separate them by response, and this one does not predict response to any medication. It reads pathway-level variants — GIPR, GLP1R, FTO, and MC4R — that describe your baseline tirzepatide-relevant biology.

Why aren't the prices identical if the molecule is?

Eli Lilly prices the two labels independently, so their April 2026 list figures differ slightly despite the shared active ingredient. As always, list price is not the same as out-of-pocket cost, which depends on coverage, savings programs, the prescribed indication, and compounded-alternative availability.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.